Barber L D, Madrigal J A
The Anthony Nolan Research Institute, Royal Free Hospital, Pond Street, Hampstead, London, UK.
Vox Sang. 2006 Jul;91(1):20-7. doi: 10.1111/j.1423-0410.2006.00775.x.
Although the T-cell response to allogeneic cells is typically regarded as a detrimental phenomenon responsible for rejection of transplanted allografts and graft-vs.-host disease following haematopoietic stem cell transplantation, beneficial components also exist within the alloreactive population. Alloreactive T cells specific for tumour antigens can contribute to the elimination of malignant cells, and alloantigen-specific regulatory T cells can promote transplant tolerance. The challenge is to separate the good from the bad. We review how the identification, isolation and manipulation of beneficial alloreactive T cells has grown from a greater understanding of the molecular basis of the T-cell alloresponse and how alloaggression could be exploited for immunotherapy.
尽管对同种异体细胞的T细胞反应通常被视为一种有害现象，它会导致移植的同种异体移植物被排斥以及造血干细胞移植后发生移植物抗宿主病，但同种反应性群体中也存在有益成分。对肿瘤抗原有特异性的同种反应性T细胞有助于消除恶性细胞，而异种抗原特异性调节性T细胞可促进移植耐受。挑战在于区分好坏。我们回顾了对有益同种反应性T细胞的鉴定、分离和操控是如何基于对T细胞同种反应分子基础的更深入理解而发展起来的，以及同种攻击如何能够被用于免疫治疗。
